Daptomycin is inactivated by pulmonary surfactant but its effectiveness in hematogenous 24 pulmonary infection is poorly studied. The potential therapeutic application was evaluated in 25 a methicillin-resistant Staphylococcus aureus (MRSA) hematogenous pulmonary infection 26 mouse model. Compared with controls, daptomycin improved the survival (p < 0.001) and 27 hematogenous murine bronchopneumonia caused by methicillin-resistant and vancomycin-intermediate
decreased the number of abscesses and bacteria in the lungs (p < 0.01). Daptomycin may be 28 an effective therapeutic option for MRSA hematogenous pulmonary infection.
Methicillin-resistant Staphylococcus aureus (MRSA) is an important bacterium that 30 causes a variety of infections such as pneumonia, bacteremia, and skin and soft-tissue 31 infections. In particular, bacteremia causes by MRSA is associated with a high mortality rate, 32 even with appropriate antimicrobial treatments (1) (2) (3) . Vancomycin has been a key drug for 33 parenteral therapy for MRSA infection for many years. However, the emergence and spread 34 of vancomycin-insensitive S. aureus has become of substantial concern (4). Thus, alternative 35 drugs for the treatment of MRSA infections are required. The lipopeptide antibiotic, 36 daptomycin, has anti-MRSA activity and possesses a novel mechanism of action that does not 37 involve cell lysis (5). In a study of bloodstream infections due to MRSA that possessed 38 elevated vancomycin MICs, daptomycin treatment was associated with better outcomes than 39 vancomycin (6). For the treatment of MRSA-related lung infections including pneumonia, 40 daptomycin is not recommended because it is inactivated by the lung surfactant (7). However, 41 there are limited data on the effectiveness of daptomycin in MRSA hematogenous pulmonary 42 infection. In this study, we compared the in vivo effectiveness of daptomycin and vancomycin 43 in the treatment of mice with hematogenous pulmonary infection caused by MRSA.
44
A murine model of hematogenous pulmonary infection was generated by the 45 inoculation of the MRSA NUMR101 strain, that was enclosed in small agar beads, into the 46 tail vain of ddY mice (6-8 weeks old, male; SLC Inc, Shizuoka, Japan) as previously 47 described (8). The Ethics Review Committee for Animal Experimentation approved all 48 experimental protocols used in this study. The MIC of vancomycin and daptomycin against 49 NUMR101 were 1 (9) and 0.25µg/mL, respectively. The MIC of daptomycin was determined 50 by the broth microdilution method using Muller-Hinton II broth with 50mM Ca 2+ . Mice were 51 inoculated with the bacteria at 0.25-1 × 10 8 CFU/mouse. Treatment commenced 24 h after 52 inoculation by intraperitoneal administration of the test agent. In the daptomycin-treated 53 group, daptomycin (50mg/kg) was administered every 24 h to produce similar administration of daptomycin. In the vancomycin-treated group, the same dose of 56 vancomycin (50mg/kg) was administered every 12 h (11). For the controls, saline was 57 injected every 12 h.
58
Survival of the mice was observed for 10 days (Fig. 1 , each group; n= 17). All 59 control mice died by day 8; the survival rates on day 10 in the vancomycin-and 60 daptomycin-treated groups were 52.9% (p < 0.001 vs. controls, Log-rank test) and 94% (p < 61 0.001 vs. controls and p = 0.008 vs. vancomycin-treated group, Log-rank test), respectively.
62
To examine the histological and bacterial findings in the early phase, animals were 63 sacrificed on day 3 (at 12 h after administration of 5 doses for vancomycin and 3 doses for 64 daptomycin) and the lungs were dissected under aseptic conditions. For histological 65 examination, lung tissue was fixed in 10% buffered formalin and stained with 66 hematoxylin-eosin. The microscopic findings revealed lung abscesses including a central 67 bacterial colony (Fig. 2) . Total abscesses in a single slice were counted and lung area was 68 calculated using cross-section paper as previously described (9). The number of abscesses 69 (mean ±SD, n= 3) in a single slice of the control group was 0.297 ± 0.047 /mm 2 , however, 70 administration of vancomycin and daptomycin resulted in a significant decrease in the 71 number of abscesses (0.107 ± 0.015 and 0.040 ± 0.010/mm 2 , respectively; p < 0.01 vs. 72 controls, Scheffe's test following the Kruskal-Wallis test) ( Fig. 3 ). There was no significant 73 difference between these two groups (p = 0.08) but this may be due to small number of 74 samples.
75
For microbiological examination, the lungs were suspended in 1 mL of saline, 76 homogenized and cultured quantitatively as previously described (9) (Fig. 4) . The number of 77 bacteria (mean ± SEM, n=6) in the lungs of the control group was 7.25 ± 0.26 log 10 CFU/mL. decreased the number of viable MRSA cells compared with controls (p < 0.01, Scheffe's test 81 following the Kruskal-Wallis test), but there was no significance between the vancomycin-82 and daptomycin-treated groups. Similarly, statistical significance between these two groups 83 was not observed on day 6 (late phase). These findings seemed not to be consistent with the 84 result of survivals; however, our data can include the number of bacteria in the pulmonary 85 vessels. In this model, perfusion with physiological saline through the pulmonary vessels was 86 not performed because of concerns that it would wash out the bacteria in the abscesses.
87
Daptomycin is known to have a good distribution, and it penetrates well into the 88 inflammatory sites (12); it has been confirmed to have potent antibacterial activity and long 89 postantibiotic effects in murine thigh infection models (13-14). These advantages in 90 pharmacodynamics and pharmacokinetics may explain the outcomes in this study. Our study 91 suggested that daptomycin may be an effective therapeutic option for MRSA hematogenous 92 pulmonary infection. It has been reported that daptomycin was used successfully in septic 93 pulmonary emboli (15, 16), despite of inactivation of daptomycin by pulmonary surfactant.
94
Unlike pneumonia, in which there is bacterial growth in the alveolar space, hematogenous 95 infections may be little affected by the surfactant. Bacteria, probably originated from the 96 nearby abscess, were also observed in the air space in this model, but we considered the 97 bacteria to mainly have been in the abscess formations. However, our results do not imply 98 that daptomycin is superior to vancomycin in the treatment of septic pulmonary emboli due to 99 MRSA, because we did not determine the concentrations of each antibiotic in this model. In 100 addition, the dose of vancomycin used in this study (50mg/kg, twice daily) can be lower than 101 the estimated clinical dose (110mg/kg twice daily in mice) (17).
102
In conclusion, daptomycin may be effective in MRSA hematogenous pulmonary 103 infection. However, further studies will be required to elucidate the potential benefit in The number of abscesses per mm 2 was counted. The number (mean ± SD) of lung abscesses per mm 2 in the control and vancomycin-and daptomycin-treated groups was 0.297 ± 0.047, 0.107 ± 0.015, and 0.040 ± 0.010/mm 2 , respectively (n = 3 for all groups) (*p < 0.01 vs. control). The numbers (mean ± SEM) of bacteria in the control and vancomycin-and daptomycin-treated groups were 7.25 ± 0.26, 4.67 ± 0.17, and 4.36 ± 0.20 log 10 cfu/mL (n = 6 for all groups), respectively (*p < 0.01 vs. control).
